Journal of Clinical Oncology
Articles in this Issue
Partial versus radical nephrectomy for renal cell carcinoma: A systematic review and meta-analysis.
e16551 Background: Renal cell carcinoma (RCC) is a common urological challenge, for which radical nephrectomy (RN) has ser...
Clinical impact of baseline and peri-treatment concomitant medication exposure and polypharmacy on outcomes of immune checkpoint inhibitor therapy: A real-world pan-tumor analysis.
11011 Background: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet real-world patients frequently...
Survival outcomes of high and intermediate-risk hormone receptor (HR)-positive human epidermal growth receptor-2 (HER2)-negative early breast cancer patients (EBC) who did and did not receive (neo)adjuvant chemotherapy.
e12530 Background: Patients with HR-positive HER2-negative EBC have protracted risk of disease relapse despite 5 years of...
Effects of SFRT on quality of life in patients with bulky advanced cancer: A retrospective single-center cohort analysis.
e24058 Background: Bulky tumors remain a major therapeutic challenge in modern oncology. Spatially Fractionated Radiation...
Three-decade trends in bladder cancer burden in the Middle East and North Africa: Divergent patterns between regional and Saudi Arabian populations.
e16616 Background: Urinary bladder cancer (UBC) represents a significant public health challenge in the Middle East and No...
Sequential bTAE-HAIC combined with lenvatinib and sintilimab for infiltrative hepatocellular carcinoma: A single-center perspective.
4131 Background: Infiltrative hepatocellular carcinoma (HCC) is defined as a tumor with ill-defined border, no evidence of...
Real-world effectiveness of pembrolizumab among patients with TMB-H advanced solid tumors.
e23360 Background: Pembrolizumab has been conditionally approved for previously treated solid tumor patients with high tum...
Admission acuity and inpatient outcomes across major gastrointestinal malignancies in the United States, 2018–2022.
11097 Background: Hospitalization for gastrointestinal (GI) malignancies frequently occurs in the setting of acute decompe...
Enabling federated discovery leveraging agentic AI systems: The Cancer AI Alliance and DataVoyager.
e20516 Background: Artificial intelligence (AI) has the potential to transform oncology, but robust AI models require dive...
Negative hyperselection as a predictive biomarker of benefit from first-line doublets + anti-EGFRs/bevacizumab (bev) in microsatellite stable (pMMR/MSS) <i>RAS</i> and <i>BRAF</i> wild-type (wt) and HER2− metastatic colorectal cancer (mCRC): An individual patient data pooled analysis of seven clinical trials (CTs).
3550 Background: Primary tumor sidedness is nowadays a major driver for the choice of biologics in the first line of pMMR/...
Real-world outcomes of prolonged versus shorter duration pembrolizumab following chemoradiation in non–small cell lung cancer: A propensity-matched analysis.
e20636 Background: The optimal duration of pembrolizumab following chemoradiation in non–small cell lung cancer (NSCLC) re...
Patient priorities for a digital health platform to support Lynch syndrome surveillance and research engagement: A needs assessment survey.
e22556 Background: Lynch syndrome requires lifelong, multi-organ surveillance and ongoing family communication to enable c...
A multi-center phase II study of chemotherapy (SOX) plus tislelizumab as first-line therapy for gastric cancer with liver metastasis.
e16047 Background: Grim prognosis and medical scarcities of gastric cancer (GC) with liver metastasis (LM) presents the si...
Assessment of racial and ethnic reporting in clinical trials cited by the NCCN bladder cancer treatment guidelines.
e23125 Background: Clinical trials cited in national treatment guidelines are standard references of care. However, the ex...
Lung cancer and stroke mortality trends in middle-aged and older US adults, 1999-2023: A CDC WONDER analysis.
e20774 Background: Lung cancer is the leading cause of cancer mortality in the U.S., while stroke ranks fourth overall. Sh...
Patient-reported barriers to treatment access and home delivery in rare cancers across five European countries.
1551 Background: Patients with rare diseases, including rare cancers, frequently experience barriers to timely treatment a...
Impact of Medicaid expansion on survival across five cancer types.
e23036 Background: Prior population-based registry studies found Medicaid expansion is associated with improved cancer sur...
Clinical characterization and association with autoimmunity in immune checkpoint inhibitor (ICI)–mediated thyroid dysfunction in a real-world sample.
e24159 Background: ICI mediated thyroid dysfunction (TD) usually presents as transient hyperthyroidism followed by hypothy...
Impact of GLP-1 receptor agonists in hormone receptor–positive breast cancer patients receiving CDK4/6 inhibitors.
1100 Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes and...
A harmonized workflow to enable efficient tumor-normal matched whole genome sequencing from HMW gDNA and FFPE samples.
e15116 Background: Whole genome sequencing (WGS) in clinical oncology offers a comprehensive approach to tumor genomic pro...
A phase 1/2, first-in-human, open-label, dose-escalation and -expansion study of TAK-188, a novel antibody-drug conjugate (ADC) targeting CCR8 <sup>+</sup> regulatory T cells, in adult patients with locally advanced or metastatic solid tumors.
TPS3155 Background: Regulatory T cells (Tregs) are key contributors to an immunosuppressive tumor microenvironment (TME)....
Expression levels of clock genes <i>PER2</i> and <i>PER3</i> in nasopharyngeal carcinoma and their correlation with survival prognosis and other factors.
e18055 Background: Nasopharyngeal carcinoma is a malignant tumor of the head and neck that originates from the mucosal epi...
Phase II study of bipolar androgen therapy combined with sipuleucel-T for patients with metastatic castration resistant prostate cancer (mCRPC).
e17081 Background: Bipolar androgen therapy (BAT) is an investigational therapy comprising monthly supraphysiologic testos...
Longitudinal ecological momentary assessment compliance among patients with cancer pain.
e23017 Background: Ecological momentary assessments (EMA) allow for frequent assessments and reduce retrospective reportin...
Donafenib plus transarterial chemoembolization (TACE) with or without anti–PD-1 antibodies for unresectable hepatocellular carcinoma second-line or later therapies: A retrospective multicenter study.
e16208 Background: Currently , there is still unsatisfactory effect of treatment regimen for patients with hepatocellular...